Stromal POSTN Enhances Motility of Both Cancer and Stromal Cells and Predicts Poor Survival in Colorectal Cancer.
cancer-associated fibroblasts (CAFs)
colorectal cancer (CRC)
immunohistochemistry
migration
periostin (POSTN)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Jan 2023
18 Jan 2023
Historique:
received:
19
11
2022
revised:
04
01
2023
accepted:
16
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
Evidence for the tumor-supporting capacities of cancer-associated fibroblasts (CAFs) has rapidly been accumulating. To uncover clinicopathological importance of periostin (POSTN) expression in colorectal cancer (CRC), the present study immunohistochemically examined its expression status. Furthermore, to reveal its mechanisms involved, molecular experiments were performed. In CRC tissues, 44% of the cases (119/269) exhibited POSTN expression in the CAFs. In contrast, CRC cells expressed POSTN at almost undetectable levels. Survival analyses identified that patients with POSTN-positive CRC had a significantly worse 5-year survival rate (63.2% vs. 81.2%;
Identifiants
pubmed: 36765564
pii: cancers15030606
doi: 10.3390/cancers15030606
pmc: PMC9913098
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K07410
Références
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7551-6
pubmed: 27317748
J Clin Invest. 2002 May;109(9):1143-8
pubmed: 11994402
J Pathol Clin Res. 2017 Oct 07;3(4):268-278
pubmed: 29085667
Oncotarget. 2016 Jan 5;7(1):798-813
pubmed: 26556874
World J Gastroenterol. 2016 Jun 21;22(23):5301-16
pubmed: 27340347
Cancer Cell Int. 2022 Oct 12;22(1):315
pubmed: 36224629
Oncogene. 2007 Mar 29;26(14):2082-94
pubmed: 17043657
Cell Tissue Res. 2016 Sep;365(3):453-65
pubmed: 27234502
Cancer Res. 2013 Dec 15;73(24):7313-23
pubmed: 24165159
Biochem Soc Trans. 2017 Feb 8;45(1):229-236
pubmed: 28202677
J Cell Biol. 2017 Nov 6;216(11):3509-3520
pubmed: 28931556
Mol Cell Biol. 2005 Dec;25(24):11131-44
pubmed: 16314533
Front Pharmacol. 2022 Jan 18;12:772926
pubmed: 35115926
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancers (Basel). 2021 Sep 21;13(18):
pubmed: 34572947
Cell Rep. 2020 Jan 21;30(3):793-806.e6
pubmed: 31968254
J Pathol. 2020 Feb;250(2):205-216
pubmed: 31639216
Biomedicines. 2021 Aug 04;9(8):
pubmed: 34440160
Oncogene. 2011 Feb 10;30(6):714-23
pubmed: 20972463
Biochem J. 1993 Aug 15;294 ( Pt 1):271-8
pubmed: 8363580
Cancer Res. 2013 Sep 15;73(18):5657-68
pubmed: 23903958
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Int J Mol Sci. 2022 Mar 02;23(5):
pubmed: 35269894
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Pathol Int. 2021 May;71(5):316-324
pubmed: 33631042
Nat Genet. 2017 May;49(5):708-718
pubmed: 28319088
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Gut. 2020 Jul;69(7):1269-1282
pubmed: 31685519
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
J Exp Med. 2018 Dec 3;215(12):3075-3093
pubmed: 30470719
Int J Mol Sci. 2022 Mar 17;23(6):
pubmed: 35328677
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14338-42
pubmed: 9405613
Virchows Arch. 2021 Aug;479(2):277-284
pubmed: 33638656
J Pathol Transl Med. 2017 May;51(3):306-313
pubmed: 28407462